22 related articles for article (PubMed ID: 34642926)
1. Relationship of Hearing Loss to Parkinson's Disease, Dementia, and APOE Genotype in Adults.
Cha CH; Lin TK; Wu CN; Yang CH; Huang YW; Hwang CF
Medicina (Kaunas); 2024 Apr; 60(5):. PubMed ID: 38792885
[No Abstract] [Full Text] [Related]
2. 2-Methoxyestradiol and Hydrogen Peroxide as Promising Biomarkers in Parkinson's Disease.
Bastian P; Konieczna L; Dulski J; Daca A; Jacewicz D; Płoska A; Knap N; Sławek J; Bączek T; Kalinowski L; Drzeżdżon J; Roszmann A; Belka M; Górska-Ponikowska M
Mol Neurobiol; 2024 Jan; 61(1):148-166. PubMed ID: 37589832
[TBL] [Abstract][Full Text] [Related]
3. Research Evidence of the Role of the Glymphatic System and Its Potential Pharmacological Modulation in Neurodegenerative Diseases.
Verghese JP; Terry A; de Natale ER; Politis M
J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498538
[TBL] [Abstract][Full Text] [Related]
4. Genetic architecture of Parkinson's disease subtypes - Review of the literature.
Dulski J; Uitti RJ; Ross OA; Wszolek ZK
Front Aging Neurosci; 2022; 14():1023574. PubMed ID: 36337703
[TBL] [Abstract][Full Text] [Related]
5. The role of APOE in cognitive trajectories and motor decline in Parkinson's disease.
Jo S; Kim SO; Park KW; Lee SH; Hwang YS; Chung SJ
Sci Rep; 2021 Apr; 11(1):7819. PubMed ID: 33837234
[TBL] [Abstract][Full Text] [Related]
6. An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF Aß42 and an APOE ε4 allele.
Shahid M; Kim J; Leaver K; Hendershott T; Zhu D; Cholerton B; Henderson VW; Tian L; Poston KL
Neurobiol Dis; 2019 Jul; 127():278-286. PubMed ID: 30826425
[TBL] [Abstract][Full Text] [Related]
7. The impact of common genetic variants in cognitive decline in the first seven years of Parkinson's disease: A longitudinal observational study.
Chung J; Ushakova A; Doitsidou M; Tzoulis C; Tysnes OB; Dalen I; Pedersen KF; Alves G; Maple-Grødem J
Neurosci Lett; 2021 Nov; 764():136243. PubMed ID: 34509566
[TBL] [Abstract][Full Text] [Related]
8. GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study.
Szwedo AA; Dalen I; Pedersen KF; Camacho M; Bäckström D; Forsgren L; Tzoulis C; Winder-Rhodes S; Hudson G; Liu G; Scherzer CR; Lawson RA; Yarnall AJ; Williams-Gray CH; Macleod AD; Counsell CE; Tysnes OB; Alves G; Maple-Grødem J;
Mov Disord; 2022 May; 37(5):1016-1027. PubMed ID: 35106798
[TBL] [Abstract][Full Text] [Related]
9. APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease.
Tropea TF; Xie SX; Rick J; Chahine LM; Dahodwala N; Doshi J; Davatzikos C; Shaw LM; Van Deerlin V; Trojanowski JQ; Weintraub D; Chen-Plotkin AS
Mov Disord; 2018 Feb; 33(2):289-297. PubMed ID: 29168904
[TBL] [Abstract][Full Text] [Related]
10. Effects of sex and APOE on Parkinson's Disease-related cognitive decline.
Tipton PW; Bülbül N; Crook J; Quicksall Z; Ross OA; Uitti RJ; Wszolek ZK; Ertekin-Taner N
Neurol Neurochir Pol; 2021; 55(6):559-566. PubMed ID: 34642926
[TBL] [Abstract][Full Text] [Related]
11. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
Rolinski M; Fox C; Maidment I; McShane R
Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
[TBL] [Abstract][Full Text] [Related]
12. Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment.
Kulisevsky J; Pagonabarraga J
Mov Disord; 2009 Jun; 24(8):1103-10. PubMed ID: 19353727
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
